Your browser doesn't support javascript.
Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma.
Yang, Shenmiao; Dong, Dong; Gu, Hongfei; Gale, Robert Peter; Ma, Jun; Huang, Xiaojun.
  • Yang S; Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No.11, Xizhimen Nan Street, Beijing, 100044, China.
  • Dong D; JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong SAR, China.
  • Gu H; Chinese Lymphoma Patients Organization, House086, Beijing, China.
  • Gale RP; Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Ma J; Harbin Institute of Hematology and Oncology, Harbin, China.
  • Huang X; Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No.11, Xizhimen Nan Street, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn.
J Cancer Res Clin Oncol ; 147(5): 1469-1479, 2021 May.
Article in English | MEDLINE | ID: covidwho-1384445
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

INTRODUCTION:

The severe acute respiratory syndrome-2 (SARS-CoV-2) pandemic disrupted medical care for persons with cancer including those with lymphoma. Many professional societies recommend postponing, decreasing, or stopping anti-cancer therapy in selected persons during the pandemic. Although seemingly sensible, these recommendations are not evidence-based and their impact on anxiety and health-related quality-of-life (HRQoL) is unknown.

METHODS:

We surveyed 2532 subjects including 1060 persons with lymphoma, 948 caregivers, and 524 normals using a purposed-designed questionnaire on a patient organization website. Respondents also completed the Zung Self-Rating Anxiety and patient respondents, the EORTC QLQ-C30 instruments to quantify anxiety, and HRQoL. We also evaluated caregiver support and an online education programme of the Chinese Society of Clinical Oncology (CSCO). Data of HRQoL from a 2019 pre-pandemic online survey of 1106 persons with lymphoma were a control.

RESULTS:

33% (95% confidence interval [CI] 30, 36%) of lymphoma patients and 31% (28, 34%) of caregivers but only 21% (17, 24%) of normals had any level of anxiety (both pair-wise P < 0.001). Among lymphoma respondents, physical exercise and better caregiver support were associated with less anxiety, whereas female sex, receiving therapy, and reduced therapy intensity were associated with more anxiety. Paradoxically, lymphoma respondents during the pandemic had better HRQoL than pre-pandemic controls. Reduced therapy intensity was associated with worse HRQoL, whereas respondents who scored caregiver support and the online patient education programme high had better HRQoL.

CONCLUSION:

During the SARS-CoV-2 pandemic, lymphoma patients and their caregivers had significantly higher incidences of anxiety compared with normals. Lymphoma respondents reported better HRQoL compared with pre-pandemic controls. Reduced therapy intensity in persons with cancer may have unanticipated adverse effects on anxiety and HRQoL. Regular and intense support by caregivers and online education programmes alleviate anxiety and improve HRQoL.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anxiety / Quality of Life / Withholding Treatment / COVID-19 / Lymphoma Type of study: Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Cancer Res Clin Oncol Year: 2021 Document Type: Article Affiliation country: S00432-020-03426-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Anxiety / Quality of Life / Withholding Treatment / COVID-19 / Lymphoma Type of study: Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Cancer Res Clin Oncol Year: 2021 Document Type: Article Affiliation country: S00432-020-03426-0